Biogen Options Turn Defensive as Q3 Results Land

Biogen has reported Q3 results this morning, and the options market spent the past week bracing for them more aggressively than the short book did.

The clearest signal this week came from put/call positioning. The ratio climbed to 0.91, more than two standard deviations above its 20-day average of 0.78. That is close to the highest defensive reading of the past year, with the 52-week peak at 1.06. The shift in options demand has been sharp: the PCR held between 0.73 and 0.76 through most of October before jumping above 0.90 in the final days of the month. Investors were buying protection at a rate well above recent norms even as the stock continued to climb.

Short interest tells a different story. Bears have been retreating, not building. The short position fell roughly 10% over the past week to 3.8% of the free float, the lowest level in more than a month. Borrow conditions reflect that ease: cost to borrow is at 0.48%, down modestly on the week, and availability is exceptionally loose at 1,843%, meaning there are roughly 19 shares available to borrow for every one already lent out. The lending market carries no squeeze pressure at all. The ORTEX short score has drifted down from 43.5 at the start of last week to 41.0, reinforcing the picture of a short position that has been quietly unwinding into the rally.

The Street moved fast ahead of the print. JP Morgan's Chris Schott upgraded to Overweight on October 12, raising his target from $210 to $300. Wells Fargo lifted its target from $250 to $310. B of A raised its target to $244 while staying at Neutral. The consensus mean target is now $248, fractionally below the current price of $252.73, but the most active recent movers are clustered $50 to $60 above the market. The analyst recommendation differential ranks in the 93rd percentile, among the most bullishly skewed setups in the market. The P/E multiple has expanded 1.3 points over the past 30 days to 16.1x. Earnings yield ranks in the 85th percentile, a signal the Street still considers the stock reasonably valued relative to earnings power despite the recent run.

The debate between bulls and bears centres on Biogen's transition away from its legacy multiple sclerosis franchise. The bull case rests on Leqembi, which hit $511 million in 2025 revenue, up 140% year on year, and Skyclarys at $520 million, up 36%, alongside pipeline optionality in litifilimab and a possible $2 billion-plus lupus opportunity. The bear case is that Avonex, Tysabri, and Tecfidera remain large parts of the revenue base and are all declining, while Spinraza's $1.5 billion in 2025 sales fell 2% year on year. The stock has gained 4% over the past week and 11% over the past month, outpacing the peer group: AMGN rose 2% on the week, GILD added 1.6%, and ABBV slipped 0.9%.

Retail attention has also picked up. Wikipedia page views and ORTEX stock-page traffic are running 1.85 standard deviations above Biogen's own 90-day baseline, the highest attention reading in recent weeks. On the institutional side, FMR LLC last disclosed a 12.4% stake in August, up from 11.3%, the only activist-threshold holder to show a meaningful increase this year. No Schedule 13D filings are on record, and all other large holders are passive. Insider activity has been minimal: the only open-market transaction in the past 90 days was a small tax-withholding disposal by the Chief Accounting Officer, worth under $2,000.

With the Q3 numbers now in, the next focus is the company's commentary on Leqembi's commercial trajectory and any update on the litifilimab Phase III timeline.